Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria
Open Access
- 24 December 2004
- journal article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 48 (1), 156-163
- https://doi.org/10.1007/s00125-004-1607-0
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and DeathNew England Journal of Medicine, 2004
- B-type natriuretic peptide in cardiovascular diseaseThe Lancet, 2003
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003
- Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart FailureCirculation, 2002
- Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failureJournal of the American College of Cardiology, 2002
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapyAmerican Heart Journal, 1999
- Plasma N-Terminal Pro–Brain Natriuretic Peptide and AdrenomedullinCirculation, 1998
- Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarctionThe Lancet, 1993
- Individual Determination of Glomerular Filtration Rate from Plasma CreatinineScandinavian Journal of Clinical and Laboratory Investigation, 1976